stockker0 mentioned OPL........... and it has had a nice run with probably more to come. I have a position in both OPL and VRS and would not think of cashing in a single VRS share to increase my OPL. They both have game changing technologies but VRS is on the verge of bringing it's to market with a pipeline full to follow. Another factor in VRS's favour is its management team. They have my full confidence, haven't shown a misstep so far.
---------------------------------------------------
December 5, 2012
Brian Marckx, CFA, of Zacks Investment Research, comments on the recent developments of Verisante Technology, Inc. Mr. Marckx writes:
"...We continue to believe that (as we first detailed in our initiation report on VRS in Feb 2011) VRS can be highly successful over the long term based on the combination of the technology incorporated into Aura (and related competitive advantages) as well as VRS's business/revenue model. As we've explained in the past, we think Aura can be more competitive than MELA Science's Melafind device from a clinical perspective (for a number of reasons including superior accuracy, menu of indicated uses/label, speed of scans, probe size).
"...Aura could be very well received upon launch (particularly given potentially significant advantages of Aura over Melafind) and begins to answer the question about whether lack of reimbursement will be a deal-killer (it appears it will not be) for physicians/clinics/hospitals to buy (or lease) the device and for patients to pay out-of-pocket for an exam. And as a reminder, while VRS's Europe/Canada/Australia launch will likely initially target dermatologists, Aura is not restricted to use only by dermatologists which opens the door for VRS to detail to other health care providers including general physicians, skin care clinics, oncology practices, and imaging centers"
Read the entire update from Mr. Marckx at:
https://finance.yahoo.com/news/vrs-v-q3-core-data-200000333.html